GlassScriptPhysician profile
Susan E Mitchell-Derenski
NPI 1629329578
$13,897.42
in general payments reported to CMS, 2019-2025
23 companies · $56.00 in 2025
The $56.00 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,113 · 2022: $6,399 · 2023: $831 · 2024: $498 · 2025: $56.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.15 |
| Education | $175.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $7,247.57 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $4,417.51 | 2021 | |
| Abbvie INC. | $497.94 | 2021-2023 | |
| Astellas Pharma US INC | $256.78 | 2024 | Veozah |
| Merz North America, INC. | $153.30 | 2024 | |
| Myovant Sciences INC. | $125.77 | 2021-2022 | |
| Edwards Lifesciences Corporation | $124.29 | 2022 | |
| Glaxosmithkline, LLC. | $122.78 | 2022 | |
| Kyowa Kirin, INC. | $121.83 | 2023 | Nourianz |
| Avanir Pharmaceuticals, INC. | $120.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $109.85 | 2023 | Fasenra |
| Genentech USA, INC. | $106.00 | 2021 | |
| Amgen INC. | $98.70 | 2023 | Repatha |
| Novo Nordisk INC | $83.46 | 2023 | Wegovy |
| Agile Therapeutics, INC. | $74.57 | 2021-2024 | Twirla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $65.90 | 2021-2023 | Phexxi |
| Idorsia Pharmaceuticals US INC | $46.24 | 2023 | Quviviq |
| Exeltis, USA INC. | $31.46 | 2021-2024 | Slynd |
| Sumitomo Pharma America, INC. | $23.02 | 2024 | Myfembree |
| Hologic Sales and Service, LLC | $21.06 | 2022 | |
| Mayne Pharma Commercial LLC | $21.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.65 | 2021 | |
| Therapeuticsmd, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Mitchell-Derenski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.